Insider · CIK 0001663022

Haviland Kate

Reports to the SEC for 4 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001663022

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-30	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+32K sh	—	—	32,000
2026-06-09	BCAXBicara Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19.5K sh	—	—	19,475
2026-04-29	AVLNAvalyn Pharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27K sh	—	—	26,978
2025-07-17	Blueprint Medicines CorpA Award	Director, Chief Executive Officer	AAward	+129K sh	—	—	295,139
2025-07-17	Blueprint Medicines CorpD Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−224K sh	—	—	70,729
2025-07-17	Blueprint Medicines CorpU Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−70.7K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−2 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−591 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−39K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−32.5K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−28.5K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−26.1K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−80K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−80K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−80K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−70.4K sh	—	—	0
2025-06-26	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+36K sh	—	—	36,000
2025-06-09	BCAXBicara Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+23.7K sh	—	—	23,746
2025-04-01	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−600 sh	$85.47	−$51.3K	167,827
2025-04-01	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−598 sh	$86.14	−$51.5K	167,229
2025-04-01	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−1,200 sh	$87.34	−$105K	166,029
2025-04-01	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−100 sh	$88.59	−$8,859	165,929
2025-03-05	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−16.2K sh	$88.80	−$1.43M	168,427
2025-03-01	Blueprint Medicines CorpA Award	Director, Chief Executive Officer	AAward	+35.2K sh	—	—	184,578
2025-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+70.4K sh	—	—	70,400
2025-01-21	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−1,446 sh	$110.24	−$159K	149,378
2024-11-29	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−400 sh	$95.40	−$38.2K	152,777
2024-11-29	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−1,746 sh	$96.74	−$169K	151,031
2024-11-29	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−207 sh	$97.76	−$20.2K	150,824
2024-09-12	BCAXBicara Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+23.7K sh	—	—	23,746
2024-06-17	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2024-03-07	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−12.5K sh	$90.69	−$1.13M	153,177
2024-03-01	Blueprint Medicines CorpA Award	Director, Chief Executive Officer	AAward	+40K sh	—	—	165,641
2024-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+80K sh	—	—	80,000
2023-06-27	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-03-06	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−6,428 sh	$45.72	−$294K	125,853
2023-03-06	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−212 sh	$44.65	−$9,465.8	125,641
2023-03-01	Blueprint Medicines CorpA Award	Director, Chief Executive Officer	AAward	+40K sh	—	—	132,281
2023-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+80K sh	—	—	80,000
2022-11-03	Blueprint Medicines CorpP Purchase	Director, Chief Executive Officer	PPurchase	+1,100 sh	$43.98	+$48.4K	92,281
2022-06-27	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19K sh	—	—	19,000
2022-03-07	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−1,048 sh	$56.18	−$58.9K	91,181
2022-03-03	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−1,719 sh	$60.27	−$104K	92,229
2022-03-01	Blueprint Medicines CorpA Award	Director, Chief Executive Officer	AAward	+40K sh	—	—	93,948
2022-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+80K sh	—	—	80,000
2021-12-13	Blueprint Medicines CorpM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+1,000 sh	$36.05	+$36.1K	54,948
2021-12-13	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−285 sh	$99.65	−$28.4K	54,663
2021-12-13	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−210 sh	$98.50	−$20.7K	54,453
2021-12-13	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−411 sh	$97.60	−$40.1K	54,042
2021-12-13	Blueprint Medicines CorpS Sale	Director, Chief Executive Officer	SSale	−94 sh	$96.78	−$9,097.32	53,948

Recent filings

Accepted (ET)
Jul 24
Haviland Kate0001193125-26-294692
SEC(opens sec.gov)
Jun 104
Haviland Kate0001628280-26-042253
SEC(opens sec.gov)
May 14
Haviland Kate0001193125-26-201865
SEC(opens sec.gov)
Jul 214
Haviland Kate0001104659-25-069386
SEC(opens sec.gov)
Jun 304
Haviland Kate0000950170-25-091582
SEC(opens sec.gov)
Jun 104
Haviland Kate0002023658-25-000079
SEC(opens sec.gov)
Apr 34
Haviland Kate0001415889-25-009959
SEC(opens sec.gov)

Companies

Address

C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET

CAMBRIDGE, MA, 02139